1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Approvals

Podcast: Noticing Neffy – A ‘Transformative Treatment’ For Type 1 Allergies

 
• By Anabel Costa-Ferreira

Richard Lowenthal, co-founder and CEO of ARS Pharmaceuticals, highlights the crucial unmet need for needle-free devices to treat type 1 allergic reactions, given challenges associated with current epinephrine injectors. Hear what’s next for the Neffy intranasal spray and ARS Pharmaceuticals.

In Vivo Podcast

[Editor’s note: This article appeared first in our sister publication, In Vivo.]

After a long-awaited series of research phases and trials, the FDA recently granted approval for Neffy as the ‘First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis.’

Speaking to In Vivo, Richard Lowenthal, co-founder and CEO of ARS Pharmaceuticals, Inc., looked back at successes and challenges across Neffy’s development, addressing the range of factors that led to this unmet area of need, including challenges posed by epinephrine auto-injectors.

Taking the EpiPen as a point of comparison, Lowenthal highlighted the efficacy and accessibility of Neffy as key factors with the potential to improve patient outcomes and identified points of action that ARS is hopeful to take across the next year.

From developing a lower-dose Neffy for children below 30kg to seeking regulatory approval in the UK, Canada, China, Australia, New Zealand, and Japan, the future appears bright for this growing biotech.

Timestamps:

1:04 History And Development of ARS Pharma

2:50 Where has this unmet need come from?

12:30 Making Neffy suitable for children >15kg

14:30 Trial stages and approvals

18:12 Why switch to Neffy?

23:22 Recent FDA approval

29:34 Future of ARS pharma and upcoming goals

More from Approvals

Newborn Screening Tests Among FDA Classifications

 
• By Elizabeth Orr

The US FDA has announced classifications for five device types, including four diagnostics as well as a hand cream to protect healthcare workers exposed to radiation. Two of the products are newborn screening tests.

FDA Regulations ‘Lock Out’ Clinically Proven Neuromodulation Devices

 
• By Natasha Barrow

Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.

Medtronic Announces Collaboration To Create A ‘New Era’ in Surgical Training

 
• By Brian Bossetta

Medtronic is teaming up with IRCAD North America to build high-tech training and education experiences for surgeons and medical professionals in cardiovascular, neuroscience, and minimally invasive surgical specialties. The move could also further position Medtronic to seize on the growing robotics

First AI Breast Cancer Prediction Platform Receives FDA Authorization

 
• By Natasha Barrow

Clairity’s "first-in-class" mammography-based AI screening tool, Clairity Breast, provides "equitable risk assessments," expanding access to lifesaving early detection for breast cancer, said company founder Connie Lehman.

More from Leadership

FDA Regulations ‘Lock Out’ Clinically Proven Neuromodulation Devices

 
• By Natasha Barrow

Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.

Volta Files For US FDA Approval Of Next-Gen Cardio Mapping Software After Winning Labeling Expansion

 
• By Marion Webb

Volta Medical received a labeling expansion for its AF-Xplorer mapping software to treat A-fib, which provides the clinical evidence needed to broaden US access. The company hopes for FDA clearance for its improved second-gen AF-Xplorer II software.

Execs On The Move: June 9–13, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.